201 related articles for article (PubMed ID: 2364366)
1. Clinical course of essential thrombocythemia in 147 cases.
Fenaux P; Simon M; Caulier MT; Lai JL; Goudemand J; Bauters F
Cancer; 1990 Aug; 66(3):549-56. PubMed ID: 2364366
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
[TBL] [Abstract][Full Text] [Related]
3. Essential thrombocythemia: a retrospective analysis of 39 cases.
Kwong YL; Liang RH; Chiu EK; Lie AK; Chan LC; Todd D; Chan TK
Am J Hematol; 1995 May; 49(1):39-42. PubMed ID: 7741136
[TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Randi ML; Rossi C; Fabris F; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
[TBL] [Abstract][Full Text] [Related]
5. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Randi ML; Rossi C; Fabris F; Menapace L; Girolami A
Clin Appl Thromb Hemost; 1999 Apr; 5(2):131-5. PubMed ID: 10725994
[TBL] [Abstract][Full Text] [Related]
6. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
7. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Jan; 5(1):30-6. PubMed ID: 10725980
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
13. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Barbui T; Finazzi G
Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
[TBL] [Abstract][Full Text] [Related]
14. Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.
Piccin A; Steurer M; Mitterer M; Blöchl EM; Marcheselli L; Pusceddu I; Marabese A; Bertozzi I; Corvetta D; Randi ML; Elli E; Pogliani EM; Veneri D; Perbellini O; Krampera M; Pacquola E; Gottardi M; Tiribelli M; Guella A; Innella B; Vivaldi P; De Biasi E; Sancetta R; Rocconi R; Bassan R; Gherlinzoni F; Pizzolo G; Gastl G; Cortelazzo S
Intern Emerg Med; 2015 Jun; 10(4):451-60. PubMed ID: 25585678
[TBL] [Abstract][Full Text] [Related]
15. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
16. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
17. [Essential thrombocythemia: a myeloproliferative state on the rise. Clinico-biological study and course of 44 cases].
Sánchez Fayos J; Outeiriño J; Prieto E; Pérez Saenz MA; Calabuig T; Román A; Olabarría E; Valero ML
Sangre (Barc); 1992 Feb; 37(1):17-24. PubMed ID: 1585233
[TBL] [Abstract][Full Text] [Related]
18. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
19. Essential thrombocythemia: a relative benign long-term course.
Meisel S; Shpilberg O; Ramot B; Ben-Bassat I
Isr J Med Sci; 1993 Apr; 29(4):190-4. PubMed ID: 8491569
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
Cortelazzo S; Viero P; Finazzi G; D'Emilio A; Rodeghiero F; Barbui T
J Clin Oncol; 1990 Mar; 8(3):556-62. PubMed ID: 2307991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
